This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ARMGO Pharma, Inc. Announces Data Which Supports Its Rycal Program As A Novel Approach For The Treatment Of Stress-induced Cognitive Disorders

TARRYTOWN, N.Y., Aug. 30, 2012 /PRNewswire/ -- ARMGO Pharma, Inc., a biopharmaceutical company developing innovative small molecule drugs known as "Rycals™," which act on the ryanodine receptor calcium-release channel (RyR), announced that a study published today in the prestigious scientific journal Cell reveals the underlying role of calcium leak through the RyR as an important contributor to stress-induced cognitive dysfunction.  In the published study titled "Role of Leaky Neuronal Ryanodine Receptors in Stress-Induced Cognitive Dysfunction," mice were given an orally available, brain-penetrant Rycal, known as S107, prior to and during a chronic stress protocol.  The results of behavioral tests demonstrated that stressed mice have cognitive dysfunction manifested as impaired learning and memory, increased anxiety and reduced spontaneous exploratory activity as compared to untreated control mice.  Mice treated with S107 showed significant improvement in all tested measures, including learning and memory, essentially becoming indistinguishable from normal unstressed mice.  In addition, direct electrophysiological assessment of the hippocampus showed that stressed mice had impaired neuronal signaling measured by reduced long-term potentiation (LTP), which was significantly improved after treatment with S107.  This promising and innovative research was conducted in the laboratory of ARMGO Pharma's founding scientist, Dr. Andrew Marks, Chair and Professor of Physiology and Cellular Biophysics at Columbia University College of Physicians and Surgeons.

The data generated by Dr. Marks demonstrate that orally available and brain-penetrant Rycals drugs may have therapeutic utility for the treatment of stress-induced cognitive dysfunction and a potentially broad variety of learning and memory disorders.  There is a well-established link between impaired learning and mental stress, and long-term chronic stress is a major contributor to the development of neuropsychiatric, cardiovascular and autoimmune diseases, as well as to cancer.  However, there is currently no effective therapy for common disorders characterized by stress-induced cognitive dysfunction, including post-traumatic stress disorder (PTSD).

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs